BRNS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BRNS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Barinthus Biotherapeutics's Trailing 12-Month Free Cash Flow is $-29.83 Mil, and Market Cap is $27.54 Mil. Therefore, Barinthus Biotherapeutics's FCF Yield % for today is -108.34%.
The historical rank and industry rank for Barinthus Biotherapeutics's FCF Yield % or its related term are showing as below:
During the past 6 years, the highest FCF Yield % of Barinthus Biotherapeutics was -2.69%. The lowest was -176.05%. And the median was -21.24%.
Barinthus Biotherapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.
The historical data trend for Barinthus Biotherapeutics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Barinthus Biotherapeutics Annual Data | |||||||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
FCF Yield % | Get a 7-Day Free Trial | - | -8.16 | -23.23 | -39.51 | -61.38 |
Barinthus Biotherapeutics Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
FCF Yield % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-54.56 | -52.34 | -88.94 | -155.66 | 105.41 |
For the Biotechnology subindustry, Barinthus Biotherapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Barinthus Biotherapeutics's FCF Yield % falls into.
FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Barinthus Biotherapeutics's FCF Yield % for the fiscal year that ended in Dec. 2024 is calculated as
FCF Yield % | = | Free Cash Flow | / | Market Cap |
= | -29.832 | / | 48.60388 | |
= | -61.38% |
Barinthus Biotherapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2024 is calculated as
FCF Yield % | = | Free Cash Flow | * | Annualized Factor | / | Market Cap |
= | 12.808 | * | 4 | / | 48.60388 | |
= | 105.41% |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Barinthus Biotherapeutics FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Thank you for viewing the detailed overview of Barinthus Biotherapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Joseph Scheeren | director | THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE |
Robin Wright | director | THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE |
William Enright | director, officer: Chief Executive Officer | 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878 |
Nadege Pelletier | officer: Chief Scientific Officer | C/O VACCITECH PLC, UNIT 6-10, ZEUS BUILDING RUTHERFORD AVENUE, HARWELL, DIDCOT X0 OX11 0DF |
Gemma Brown | officer: Chief Financial Officer | VACCITECH PLC, UNIT 6-10, ZEUS BUILDING, RUTHERFORD AVENUE, HARWELL, DIDCOT X0 OX11 0DF |
Graham Griffiths | officer: Chief Business Officer | THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE |
Christopher Ellis | officer: Chief Operating Officer | THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE |
Anne M. Phillips | director | C/O TREVENA, INC., 1018 WEST 8TH AVENUE, KING OF PRUSSIA PA 19406 |
Oxford Science Enterprises Plc | 10 percent owner | 46 WOODSTOCK ROAD, OXFORD X0 OX2 6HT |
Karen A Dawes | director | 579 BELLEVUE AVE, NEWPORT RI 02840 |
Pierre A. Morgon | director | THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE |
Margaret Marshall | officer: Chief Medical Officer | THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE |
Thomas George Evans | officer: Chief Scientific Officer | THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE |
Alex Hammacher | director | THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE |
Georgy Egorov | officer: Chief Financial Officer | THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE |
From GuruFocus
By Marketwired • 11-25-2024
By Marketwired • 03-20-2025
By Marketwired • 08-08-2024
By GuruFocus News • 03-20-2025
By sperokesalga sperokesalga • 03-28-2023
By Marketwired • 10-01-2024
By Marketwired • 06-06-2024
By Marketwired • 11-06-2024
By Marketwired • 05-22-2024
By Marketwired • 09-13-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.